<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bioresorbable scaffold coronary artery stents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bioresorbable scaffold coronary artery stents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bioresorbable scaffold coronary artery stents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Dawn Abbott, MD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H103379741"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most commercially available drug-eluting intracoronary stents (DES) consist of a metallic scaffold, a polymer coating (which may be durable or bioresorbable), and an antirestenotic drug that is mixed within the polymer and released over a period of weeks to months after implantation  (<a class="graphic graphic_table graphicRef65603" href="/d/graphic/65603.html" rel="external">table 1</a>). The use of current-generation DES is associated with low rates of restenosis, target lesion revascularization, and stent thrombosis compared with early-generation DES or bare metal stents. However, major adverse cardiovascular events such as restenosis or stent thrombosis continue at a low rate after one year with approved, commercially available, current-generation stents. (See  <a class="medical medical_review" href="/d/html/1587.html" rel="external">"Intracoronary stent restenosis"</a> and  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p>Ongoing research aims to lower the risk of these stent-related adverse cardiovascular outcomes by manipulating one or more components of the stent: the scaffold, the polymer, or the drug.</p><p>This topic will focus on efforts to further lower the rate of adverse events by eliminating the metallic stent. Ultra-thin stents are discussed separately. (See  <a class="medical medical_review" href="/d/html/1575.html" rel="external">"Intracoronary stents: Stent types", section on 'Ultra-thin-strut bioresorbable drug-eluting stents'</a>.)</p><p>Other relevant topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1575.html" rel="external">"Intracoronary stents: Stent types"</a>.)</p><p></p><p class="headingAnchor" id="H103379891"><span class="h1">ADVANTAGES AND DISADVANTAGES OF CURRENT-GENERATION SCAFFOLDS</span><span class="headingEndMark"> — </span>Current-generation drug-eluting intracoronary stents (DES) contain a metal backbone that almost entirely eliminates acute or subacute recoil of the stented coronary artery compared with balloon angioplasty. In addition, they decrease the likelihood and extent of late lumen loss and restenosis of the treated segment. As restenosis is uncommonly seen 9 to 12 months after the procedure, the need for stent scaffolding after this period is likely limited. (See  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview", section on 'Benefits of stenting'</a>.)</p><p>Potential long-term adverse consequences of the metallic stent include permanent side branch occlusion, restriction of noninvasive imaging of coronary arteries with multislice computed tomography and magnetic resonance imaging, and interference with the ability to place a bypass graft at the stented site. </p><p>The development of some late adverse events after placement of permanent metallic stents, such as restenosis or stent thrombosis, has been attributed to persistent inflammation, impaired vasomotion, ongoing tissue growth within the stent frame, and neoatherosclerosis [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H3746056340"><span class="h1">RATIONALE FOR BIORESORBABLE SCAFFOLD STENTS</span><span class="headingEndMark"> — </span>Fully biodegradable stents, which are also referred to as bioresorbable stents or bioresorbable scaffolds, have the potential to overcome some of the disadvantages of metal stents. With these devices, the scaffold is in place only long enough to protect against subacute closure, wall recoil, and early restenosis. Most of them provide vascular scaffold support for up to one year, after which time they will have completely resorbed. The use of these devices is hoped to improve outcomes in patients who need repeat percutaneous coronary intervention or coronary artery bypass graft surgery. </p><p>The disadvantages of these devices are that first-generation scaffolds had thicker struts compared with current-generation stents, were more difficult to implant than metal alloy stents, and can fracture with overdeployment from balloon dilation. In addition, the radio-opacity was poor, so visualization of deployed scaffold was difficult. Other potential limitations have been cited [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4183678431"><span class="h1">BIORESORBABLE SCAFFOLDS</span><span class="headingEndMark"> — </span>A bioresorbable vascular stent (the Absorb stent) was approved for use by the US Food and Drug Administration in 2016, but uptake was low in the United States [<a href="#rid3">3</a>]. Sale was halted worldwide by the manufacturer in September 2017 due to an increase in observed late myocardial infarction (MI) and scaffold thrombosis. Other bioresorbable scaffolds are under evaluation. In the United States, there are no approved bioresorbable vascular scaffolds. The European Medicines use of Certificate of Conformity (CE marking) bioresorbable scaffold devices is discouraged outside of clinical trials [<a href="#rid4">4</a>]. </p><p>Early trials using a variety of scaffolding materials provided the basis for the current generation of bioresorbable scaffolds under investigation [<a href="#rid5">5-11</a>]. </p><p class="headingAnchor" id="H4257379190"><span class="h2">Poly(L)-lactic acid scaffold</span><span class="headingEndMark"> — </span>There is no evidence that poly(L)-lactic acid (PLLA) scaffolds are superior to current-generation metallic stents. The Absorb and NeoVas stents are representative of this group.</p><p>The Absorb bioresorbable vascular scaffold (BVS) consists of a 150-mcm-thick bioresorbable PLLA scaffold with a 7-mcm-thick bioresorbable PLLA coating polymer, and eluted <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>.</p><p>Randomized trials have compared the efficacy and safety of the Absorb BVS with everolimus-eluting metallic stents (EES): ABSORB II [<a href="#rid12">12</a>], EVERBIO II [<a href="#rid13">13</a>], ABSORB Japan [<a href="#rid14">14</a>], ABSORB III [<a href="#rid1">1</a>], ABSORB China [<a href="#rid15">15</a>], TROFI II [<a href="#rid16">16</a>], and AIDA [<a href="#rid17">17</a>]. A 2017 meta-analysis of these randomized trials (n = 5583) came to the following conclusions at a median follow-up of two years [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with metallic EES, the risk of target lesion failure was higher with the Absorb BRS (9.6 versus 7.2 percent; absolute risk difference +2.4 percent; risk ratio 1.32; 95% CI 1.10-1.59).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of stent thrombosis was higher with the Absorb BVS (2.4 versus 0.7 percent; absolute risk difference +1.7 percent; risk ratio 3.15; 95% CI 1.87-5.30). (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Very late stent thrombosis'</a>.)</p><p></p><p>Other meta-analyses of these studies came to similar conclusions [<a href="#rid19">19-23</a>]. Thus, these early studies suggested no advantage for efficacy and a higher rate of stent thrombosis and target vessel failure for the Absorb BVS for up to three years [<a href="#rid24">24,25</a>]. </p><p>At least two additional studies of the Absorb BVS have been published after the meta-analysis [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The small ISAR-Absorb MI trial found no significant difference between the Absorb BVS and an EES with regard to an angiographic endpoint at six to eight months [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In ABSORB IV, 2604 patients with stable or unstable coronary artery disease were randomly assigned to Absorb BVS or a metallic EES [<a href="#rid27">27</a>]. Two important differences between ABSORB IV and prior trials were that the device was implanted using optimized technique learned from the prior trials and that lesion selection was more restrictive (for example, there was an attempt to avoid stenting smaller arteries). </p><p></p><p class="bulletIndent1">There was no significant difference between the two stents with regard to a composite endpoint of cardiac death, target vessel MI, and ischemia-driven target lesion revascularization at 30 days or one year (5.0 versus 3.7 percent and 7.8 versus 6.4 percent, respectively). </p><p></p><p>NeoVas is a second PLLA stent that elutes <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> from a poly(D,L-lactide) coating. The total strut thickness is 170 mcm. In vivo, porcine studies have demonstrated that the PLLA polymer is completely resorbed in approximately 36 months. In a study of 560 patients with single de novo coronary artery lesions, individuals were randomly assigned to NeoVas or to a cobalt chromium EES [<a href="#rid28">28</a>]. One-year in-segment lumen loss with NeoVas and cobalt chromium EES was similar (0.14±0.36 versus 0.11±0.34 mm, respectively; difference 0.03 mm; upper one-sided 97.5% CI 0.09 mm). Clinical outcomes at one year were similar in the two groups, as were the rates of recurrent angina (27.9 versus 32.1 percent). </p><p class="headingAnchor" id="H23524738"><span class="h2">Magnesium alloy scaffold</span><span class="headingEndMark"> — </span>Resorbable metallic scaffolds have been developed. Metals have included magnesium and iron [<a href="#rid29">29,30</a>].</p><p>The BIOSOLVE-II study treated 123 lesions in 123 patients (with stable or unstable angina or documented silent ischemia) with a sirolimus-eluting absorbable magnesium alloy scaffold (DREAMS 2G) [<a href="#rid29">29</a>]. At six months, the primary endpoint of mean in-segment late lumen loss was 0.27 mm. Angiographically detectable vasomotion was documented in 80 percent of 20 patients who were evaluated. These results compared favorably to the prior version of the stent (DREAMS 1G) [<a href="#rid31">31</a>]. Between 6 and 12 months, quantitative coronary angiography parameters remained stable [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H3167192630"><span class="h2">Polycarbonate copolymer bioresorbable scaffold</span><span class="headingEndMark"> — </span>The Fantom sirolimus-eluting bioresorbable scaffold uses a proprietary iodinated, polycarbonate copolymer of tyrosine analogs that is radiopaque, with thin struts (125 mcm). In a single-arm study of 117 patients, mean six-month in-stent late lumen loss was 0.25±0.40 mm (n = 100) [<a href="#rid33">33</a>]. The Fantom II trial prospectively enrolled 240 patients with stable or unstable angina and a single de novo coronary stenosis with reference vessel diameter 2.5 to 3.5 mm diameter and lesion length ≤20 mm. The mean in-stent late lumen loss at nine months was 0.33±0.36 mm, and in-segment binary restenosis occurred in 7.6 percent of patients. Major adverse cardiac events and target lesion failure through 12 months occurred in 4.2 percent of patients; scaffold thrombosis developed in only one patient (0.4 percent) [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H149184245"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>There are no bioresorbable scaffolds approved for use in the United States. In Europe, there are a few bioresorbable scaffolds with CE marking, but European guidelines recommend their use only in clinical trials. </p><p>Successful devices from regulatory and clinical standpoints will need to demonstrate an absorption timeframe that allows for a similar or shorter duration of dual antiplatelet therapy than available metallic drug-eluting stents. Studies must also confirm the anticipated benefit of improved long-term vessel healing (using intracoronary imaging and vasomotion responses) without an increase in adverse events of restenosis or scaffold thrombosis during the resorption period. The concept remains an attractive one, but adequately sized and well-designed clinical trials are required. </p><p class="headingAnchor" id="H103379749"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages and disadvantages </strong>–<strong> </strong>Potential long-term adverse consequences of current-generation metallic drug-eluting stents (DES) include permanent side branch occlusion, restriction of noninvasive imaging of coronary arteries, and the interference with the ability to place a bypass graft at the stented site. (See <a class="local">'Advantages and disadvantages of current-generation scaffolds'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale </strong>– Fully biodegradable stents, which are also referred to as bioresorbable stents or bioresorbable scaffolds, are being tested in clinical trials in an attempt to overcome some of the disadvantages of current-generation DES that have a metallic backbone. (See <a class="local">'Rationale for bioresorbable scaffold stents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use </strong>– There are no bioresorbable scaffolds approved for use in the United States. In Europe, there are a few bioresorbable scaffolds with CE marking, but European guidelines recommend their use only in clinical trials. (See <a class="local">'Bioresorbable scaffolds'</a> above and <a class="local">'Clinical use'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med 2015; 373:1905.</a></li><li><a class="nounderline abstract_t">Regazzoli D, Leone PP, Colombo A, Latib A. New generation bioresorbable scaffold technologies: an update on novel devices and clinical results. J Thorac Dis 2017; 9:S979.</a></li><li><a class="nounderline abstract_t">Chau KH, Kennedy KF, Messenger JC, et al. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project. JAMA Cardiol 2019; 4:564.</a></li><li><a class="nounderline abstract_t">Byrne RA, Stefanini GG, Capodanno D, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. Eur Heart J 2018; 39:1591.</a></li><li><a class="nounderline abstract_t">Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102:399.</a></li><li><a class="nounderline abstract_t">Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369:1869.</a></li><li><a class="nounderline abstract_t">Nishio S, Kosuga K, Igaki K, et al. Long-Term (&gt;10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012; 125:2343.</a></li><li><a class="nounderline abstract_t">Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371:899.</a></li><li><a class="nounderline abstract_t">Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373:897.</a></li><li><a class="nounderline abstract_t">Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122:2301.</a></li><li><a class="nounderline abstract_t">Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58:1578.</a></li><li><a class="nounderline abstract_t">Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385:43.</a></li><li><a class="nounderline abstract_t">Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015; 65:791.</a></li><li><a class="nounderline abstract_t">Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015; 36:3332.</a></li><li><a class="nounderline abstract_t">Gao R, Yang Y, Han Y, et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol 2015; 66:2298.</a></li><li><a class="nounderline abstract_t">Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016; 37:229.</a></li><li><a class="nounderline abstract_t">Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Sorrentino S, Giustino G, Mehran R, et al. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. J Am Coll Cardiol 2017; 69:3055.</a></li><li><a class="nounderline abstract_t">Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016; 387:1277.</a></li><li><a class="nounderline abstract_t">Zhang XL, Zhu L, Wei ZH, et al. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:752.</a></li><li><a class="nounderline abstract_t">Montone RA, Niccoli G, De Marco F, et al. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials. Circulation 2017; 135:2145.</a></li><li><a class="nounderline abstract_t">Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet 2017; 390:760.</a></li><li><a class="nounderline abstract_t">Zhang XL, Zhu QQ, Kang LN, et al. Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167:642.</a></li><li><a class="nounderline abstract_t">Räber L, Brugaletta S, Yamaji K, et al. Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. J Am Coll Cardiol 2015; 66:1901.</a></li><li><a class="nounderline abstract_t">Ali ZA, Gao R, Kimura T, et al. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation 2018; 137:464.</a></li><li><a class="nounderline abstract_t">Byrne RA, Alfonso F, Schneider S, et al. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J 2019; 40:167.</a></li><li><a class="nounderline abstract_t">Stone GW, Ellis SG, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet 2018; 392:1530.</a></li><li><a class="nounderline abstract_t">Han Y, Xu B, Fu G, et al. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. JACC Cardiovasc Interv 2018; 11:260.</a></li><li><a class="nounderline abstract_t">Haude M, Ince H, Abizaid A, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 2016; 387:31.</a></li><li><a class="nounderline abstract_t">Zheng JF, Qiu H, Tian Y, et al. Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months. JACC Cardiovasc Interv 2019; 12:245.</a></li><li><a class="nounderline abstract_t">Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013; 381:836.</a></li><li><a class="nounderline abstract_t">Haude M, Ince H, Abizaid A, et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J 2016; 37:2701.</a></li><li><a class="nounderline abstract_t">Abizaid A, Carrié D, Frey N, et al. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study. JACC Cardiovasc Interv 2017; 10:1832.</a></li><li><a class="nounderline abstract_t">Chevalier B, Abizaid A, Carrié D, et al. Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold. Circ Cardiovasc Interv 2019; 12:e007283.</a></li></ol></div><div id="topicVersionRevision">Topic 83567 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457558" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28894604" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New generation bioresorbable scaffold technologies: an update on novel devices and clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31066860" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020259" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908211" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544767" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508795" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-Term (&gt;10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342684" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286089" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098436" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958884" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25230593" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25720622" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26330419" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26471805" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405232" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28402237" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412389" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26825231" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27042809" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28559495" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28732815" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049539" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29089314" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30520980" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266412" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413240" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26470647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30732729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332165" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27190094" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935075" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177821" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
